TY - JOUR
T1 - COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP
AU - Busca, Alessandro
AU - Salmanton-Garcıa, Jon
AU - Corradini, Paolo
AU - Marchesi, Francesco
AU - Cabirta, Alba
AU - Blasi, Roberta Di
AU - Di Blasi, Roberta
AU - Dulery, Remy
AU - Lamure, Sylvain
AU - Farina, Francesca
AU - Weinbergerova, Barbora
AU - Batinic, Josip
AU - Nordlander, Anna
AU - Lopez-Garcıa, Alberto
AU - Drgona, L'Ubos
AU - Espigado-Tocino, Ildefonso
AU - Falces-Romero, Iker
AU - Garcia-Sanz, Ramon
AU - Garcıa-Vidal, Carolina
AU - Guidetti, Anna
AU - Khanna, Nina
AU - Kulasekararaj, Austin
AU - Maertens, Johan
AU - Hoenigl, Martin
AU - Klimko, Nikolai
AU - Koehler, Philipp
AU - Pagliuca, Antonio
AU - Passamonti, Francesco
AU - Cornely, Oliver A.
AU - Pagano, Livio
PY - 2022
Y1 - 2022
N2 - The EHA-IDWP developed an observational registry collecting data on COVID-19 infection in patients who received CAR T-cell therapy.
Prevalence of COVID-19 was 4.8%, and overall mortality was 50%, highlighting the need for prevention of infection in these patients.
AB - The EHA-IDWP developed an observational registry collecting data on COVID-19 infection in patients who received CAR T-cell therapy.
Prevalence of COVID-19 was 4.8%, and overall mortality was 50%, highlighting the need for prevention of infection in these patients.
KW - Receptors, Chimeric Antigen
KW - Receptors, Chimeric Antigen
UR - http://hdl.handle.net/10807/217384
U2 - 10.1182/bloodadvances.2021005616
DO - 10.1182/bloodadvances.2021005616
M3 - Article
SN - 2473-9529
VL - 6
SP - 2427
EP - 2433
JO - Blood advances
JF - Blood advances
ER -